A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy ...

A newly approved Alzheimer’s treatment that can slow progression of the disease won’t be subsidised by the federal government ...

Eli Lilly’s Alzheimer’s disease (AD) drug Kisunla ( donanemab) has demonstrated a growing benefit over three years in ...

The spot, which prominently utilizes a cover of “Here Comes the Sun” by The Beatles, manages to balance a message of hope with the somber nature of Alzheimer’s.

Eli Lilly and Company (NYSE:LLY) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On July 30, the company ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly Neuroscience at the end of December.

INDIANAPOLIS, July 2, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and ...

Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showing that participants treated with Kisunla (donanemab-azbt) ...

In delaying the progression of Alzheimer’s, Kisunla provides patients and their families with an “invaluable gift of time” according to its advocates. Anne White, the Executive Vice President spoke ...

Eli Lilly’s Alzheimer’s disease drug Kisunla failed to get the backing of European regulators, who said its benefits don’t outweigh the risk of potentially fatal bleeding in the brain.

Kisunla (kih-SUHN-lah) is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.